Great news! An innovative antibody drug from Gmax approved for conduct

On the occasion of the start of the year, a piece of news was sent back from the other side of the ocean that an original monoclonal antibody drug named GMA301 from Gmax has been approved by the US FDA for conducting clinical trials in the US. 

Big news! The first antibody drug for Pulmonary Arterial Hypertension

GMA301 is the first antibody drug targeting to endothelin receptor A for the treatment of pulmonary arterial hypertension, and is developed by GMAX on its independently constructed g-protein-coupled receptor (GPCR) antibody technology platform. 

Strong Team - Four Senior Experts Join Gmax Biopharm

They will provide Gmax with scientific and strategic advisory on R&D, global multi-center clinical trials, international business development and IPO, etc.

GMAX initiates the multi-region, multi-center clinical trial of Getago

GMAX initiated the multi-region, multi-center clinical trial of Getagozumab in pulmonary arterial hypertension (PAH) patients.

Gmax long-acting GLP-1R agonist has been approved by the China Human G

GMA102 has been approved for the IND in August 2018, in China. GMAX has initiated a multi-center, randomized, double-blinded, placebo controlled clinical trial in China.